Skip to main content

Table 1 Baseline characteristics of the study subjects*

From: Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients

Characteristic Ezetimibe add- on group (n = 23) Increased rosuvastatin (n = 20)
Age, years† 56.5 ± 7.4 57.0 ± 9.9
Male sex 22 (95.6) 17 (85.0)
Caucasian 19 (82.6) 15 (75.0)
Duration of ARV therapy (months)† 24 (16–34) 25(14-48)
CD4+ cell count (cells/mm3)† 580.0 ± 193 508.0 ± 208
Undetectable VL‡ 20 (87.0) 19 (95.0)
PI 21 (91.3) 17 (85.0)
NNRTI 6 (26.1) 7 (35.0)
NRTI 23 (100) 19 (95.0)
Fibrate 4 (17.4) 6 (30.0)
Antihypertensive agents 13 (56.5) 6 (30.0)
Current Smoker 6 (26.1) 1 (5.0)
Previous Smoker§ 8 (34.8) 14 (70.0)
Diabetes Mellitus 8 (34.8) 7 (35.0)
Hypertension 13 (56.5) 6 (30.0)
Family History of CVD 10 (43.5) 10 (55.0)
Body Mass Index (kg/m2)† 26.0 ± 4.2 25.3 ± 4.7
Waist Circumference, cm† 98 ± 13.7 93 ± 15.3
  1. *Data are frequency (%) unless otherwise indicated
  2. †Data are mean (±SD)
  3. ‡ < 40 copies/mL
  4. § less than one year of smoking cessation prior to study recruitment
  5. ARV, antiretroviral; VL, viral load; PI, protease inhibitor; NNRTI, non-nucleoside
  6. reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase; CVD, cardiovascular disease